Durvalumab-associated Late-onset Myocarditis Successfully Treated with Corticosteroid Therapy

We herein report a 66-year-old man with locally advanced non-small-cell lung cancer (NSCLC) who developed durvalumab-associated myocarditis. The patient underwent durvalumab administration every two weeks following concurrent chemoradiotherapy, without any adverse events or apparent disease progress...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2022/02/15, Vol.61(4), pp.527-531
Main Authors: Maetani, Tomoki, Hamaguchi, Toka, Nishimura, Takafumi, Marumo, Satoshi, Fukui, Motonari
Format: Article
Language:English
Subjects:
Adrenal Cortex Hormones - therapeutic use
Aged
Antibodies, Monoclonal
Biopsy
Carcinoma, Non-Small-Cell Lung - pathology
Case Report
Chemoradiotherapy
Chemoradiotherapy - methods
Corticosteroids
durvalumab
Dyspnea
Echocardiography
EKG
Heart diseases
Humans
Internal medicine
irAE
lung cancer
Lung Neoplasms - drug therapy
Magnetic resonance imaging
Male
Myocarditis
Myocarditis - chemically induced
Myocarditis - diagnosis
Myocarditis - drug therapy
Non-small cell lung carcinoma
Respiration
Small cell lung carcinoma
Steroids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We herein report a 66-year-old man with locally advanced non-small-cell lung cancer (NSCLC) who developed durvalumab-associated myocarditis. The patient underwent durvalumab administration every two weeks following concurrent chemoradiotherapy, without any adverse events or apparent disease progression. He presented with fatigue and dyspnea on exertion seven months after the first administration. Myocarditis was suspected based on laboratory data, an electrocardiogram, echocardiography, and magnetic resonance imaging findings. The definitive diagnosis was confirmed by a myocardial biopsy. Myocarditis was alleviated by cessation of durvalumab and corticosteroid therapy. This is a noteworthy case to describe late-onset myocarditis following the administration of durvalumab for NSCLC.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.7644-21